Evidence map›Paper›PMID 38905034›Full record

ArticleCancer biomarkers : section A of Disease markers2024

Rho GTPase-activating protein 4 is upregulated in Kidney Renal Clear Cell Carcinoma and associated with poor prognosis and immune infiltration.

Xuesong Xiao, Xiaofei Lv, Tianyu Lin, Jianqiao Li, Rui Wang, Shaoping Tian, Xinyu Liu, Shiming Liu, Huamao Jiang, Dan Yue and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xuesong XiaoDepartment of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin Medical University, Tianjin, China.
Xiaofei LvDepartment of Stomatology, The Second Hospital of Tianjin Medical University, Tianjin Medical University, Tianjin, China.
Tianyu LinDepartment of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin Medical University, Tianjin, China.
Jianqiao LiDepartment of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin Medical University, Tianjin, China.
Rui WangSchool of Medical Technology, Tianjin Medical University, Tianjin, China.
Shaoping TianSchool of Medical Technology, Tianjin Medical University, Tianjin, China.
Xinyu LiuSchool of Medical Technology, Tianjin Medical University, Tianjin, China.
Shiming LiuSchool of Medical Technology, Tianjin Medical University, Tianjin, China.
Huamao JiangDepartment of Urology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China.
Dan YueSchool of Medical Technology, Tianjin Medical University, Tianjin, China.
Yong WangDepartment of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin Medical University, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKidney Renal Clear Cell Carcinoma (KIRC) is a malignant tumor that seriously threatens human health. Rho GTPase-activating protein 4 (ARHGAP4) plays an important role in the occurrence and development of tumors.

objectiveThe purpose of this study was to explore the role of ARHGAP4 in the progression of KIRC and its diagnostic and prognostic value.

methodsMultiple analytical methods and in vitro cell assays were used to explore the expression of ARHGAP4 and its value in the progression, diagnosis and prognosis of KIRC. The biological function of ARHGAP4 was studied by GO analysis and KEGG pathway analysis, and then the relationship between ARHGAP4 and immune infiltration was analyzed.

resultsThe expression of ARHGAP4 was significantly up-regulated in KIRC. We found that the high expression of ARHGAP4 was related to the progression of KIRC and suggested a poor prognosis. Compared with normal tissues, ARHGAP4 had a better diagnostic value in KIRC. The biological function of ARHGAP4 was related to immunity, and its expression was also closely related to tumor immune infiltration and immune checkpoints.

conclusionsOur study demonstrated that ARHGAP4 may be a biomarker, which is related to the progression, diagnosis and prognosis of KIRC. Its biological functions are related to tumor immune infiltration.

Indexed as

Biomarkers, TumorCarcinoma, Renal CellGTPase-Activating ProteinsKidney NeoplasmsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisUp-RegulationBiomarkers, TumorGTPase-Activating Proteinsbiomarkerclinical prognosisimmune cell infiltrationKIRCRho GTPase-activating protein 4

Identifiers

PMID38905034
PMCPMC11307029

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.